Merck's FDA Approval and Strategic Portfolio Diversification

An in-depth look at Merck's groundbreaking FDA approval of Winrever, a novel drug for pulmonary arterial hypertension, and the strategic importance of portfolio diversification in addressing underlying diseases like fatty liver.